Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07142967 · ClinicalTrials.gov registry record · NA
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
A NA study of Intraprostatic Prostate Cancer, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT07142967 is a NA study of Intraprostatic Prostate Cancer that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07142967, a NA study of Intraprostatic Prostate Cancer, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the impact of prostate-specific membrane antigen/positron emission tomography (PSMA/PET)-informed magnetic resonance (MR)-guided radiation therapy on serious toxicity outcomes in patients with biopsy-proven locally radiorecurrent prostate cancer. The primary aim is to evaluate the safety of delivering MR-Linac-guided stereotactic body radiotherapy (SBRT) after prior prostate external beam radiotherapy for recurrent disease, and assess urinary toxicity outcomes at 2 years.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
- DRUG Androgen Deprivation Therapy (ADT)
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2029-08-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07142967
The ClinicalTrials.gov registry entry for NCT07142967 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intraprostatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT07142967 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07142967 about?
NCT07142967 is a clinical study titled "Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)". The purpose of this study is to assess the impact of prostate-specific membrane antigen/positron emission tomography (PSMA/PET)-informed magnetic resonance (MR)-guided radiation therapy on serious toxicity outcomes in patients with biopsy-proven locally radiorecurrent prostate cancer. The primary ai...
What is the current status of trial NCT07142967?
This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2025-08-15. Estimated completion is 2029-08-02.
What conditions does trial NCT07142967 study?
This clinical trial studies the following conditions: Intraprostatic Prostate Cancer.
What interventions are being tested in trial NCT07142967?
The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (RADIATION), Androgen Deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT07142967?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07142967 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.